摘要
目的观察胰岛素增敏剂文迪雅治疗2型糖尿病的临床疗效。方法对40例2型糖尿病患者在原有降糖治疗的基础上加服文迪雅治疗12周,观察治疗前后的血糖,糖基化血红蛋白,血脂及空腹胰岛素及C肽水平以及尿微量白蛋白排泄率的变化。结果空腹血糖、餐后血糖,糖基化血红蛋白,甘油三酯,空腹胰岛素,C肽水平以及尿微量白蛋白排泄率治疗后较治疗前明显下降(P<0.05)。结论文迪雅联合其他降糖药可减低胰岛素抵抗,改善胰岛素敏感性,有效控制血糖,降低尿白蛋白排泄率。
Objective To evaluate the clinical efficacy of rosiglitasone in treating type 2 diabetes. Methads Forty patients with type 2 diabetes were treated with rosiglitazone 4mg, one tim a day, for 12weeks based the last treatments. Observations were made on the changes of fast and postprandial blood glucose, HbAlc, blood lipid, fast insulin level, fast c peptide level and UAER. Results The fast glucose, postprandial blood glucose, HbAlc, fast insulin, fast c peptide level and UAER decreased significantly after rnsiglitazone trealment （P〈0.05）. Condusions Avandia may decrease insulin resistance, improve insulin sensitivity, control blood glucose effectively, decrease UAER.
出处
《海南医学》
CAS
2006年第8期19-20,共2页
Hainan Medical Journal
